Certificate published for every lotSame-day dispatch before 1pm, Monday to FridayFree Royal Mail Tracked 48 over £100
ALTAResearch peptides
Coming soonTirzepatide Pen 40 mg: ALTA box, pre-filled pen and needles
FormatPre-filled pen
AreaWeight & Metabolic
StatusComing soon
Weight & Metabolic · Pre-filled penComing soon

Tirzepatide Pen 40 mg: tirzepatide peptide pen for research

Pre-filled pen: 40 mg tirzepatide, GIP / GLP-1 dual receptor agonist

Lot certificate published at release

A sealed pre-filled pen holding 40 mg of tirzepatide, the 39-amino-acid peptide that activates both the GIP and GLP-1 receptors. Arriving soon in UK stock; register to hear the price and release date first.

Coming soonPrice to be announced
Email me when Tirzepatide Pen is available, plus new lots and offers. Unsubscribe any time. Privacy
  • Price and release date posted here first
  • Lot certificate published before it goes on sale
  • Royal Mail Tracked 48, free over £100, plain packaging
In stock now: retatrutide penThe triple agonist that adds glucagon to tirzepatide's two targets →
§ 01

Specification

Data sheet · provisional
Compound
Tirzepatide (LY3298176)
Class
Dual GIP and GLP-1 receptor agonist
Structure
39-amino-acid synthetic peptide with a C20 fatty diacid side chain
Molecular formula
C225H348N48O68
Molecular weight
4,813.5 g/mol
CAS number
2023788-19-2
Contents
40 mg tirzepatide per pen
Format
Sealed pre-filled pen; manufacturer and lot certificate confirmed at release
Storage
2 to 8 °C, protected from light. Do not freeze.
Price
Coming soon
§ 02

About Tirzepatide Pen

What tirzepatide is

Tirzepatide is a synthetic peptide, 39 amino acids long, that switches on two hormone receptors at once: GIP and GLP-1. Both hormones are released by the gut after a meal. GLP-1 slows the stomach and reduces appetite; GIP supports insulin release and appears to strengthen the appetite effect. A fatty-acid side chain lets the tirzepatide peptide bind to albumin in the blood, which gives it a half-life of about five days.

It was developed by Eli Lilly under the code LY3298176 and is the active ingredient in the licensed medicines Mounjaro and Zepbound. Our GLP-1 receptor agonists explainer covers how this family of peptides was engineered.

What the trials reported

In SURMOUNT-1, a 72-week trial in 2,539 adults with obesity published in the New England Journal of Medicine in 2022, average body-weight loss was 15.0%, 19.5% and 20.9% in the three tirzepatide arms, against 3.1% on placebo. In SURMOUNT-5, a head-to-head trial published in 2025, tirzepatide produced 20.2% average weight loss at 72 weeks against 13.7% for semaglutide. The most common side effects reported in the trials were nausea, diarrhoea, vomiting and constipation.

Tirzepatide vs semaglutide vs retatrutide

The three differ in how many receptors they act on. Semaglutide acts on one (GLP-1), tirzepatide on two (GIP and GLP-1) and retatrutide on three (GIP, GLP-1 and glucagon). In separate trials each step added weight loss: 14.9% for semaglutide (STEP 1, 68 weeks), 20.9% for tirzepatide (SURMOUNT-1, 72 weeks) and 28.3% for retatrutide (TRIUMPH-1, 80 weeks). Our retatrutide vs tirzepatide vs semaglutide comparison sets the trials side by side. The semaglutide pen is also coming soon, and the retatrutide pen and retatrutide vials are in stock now.

The 40 mg pen

The tirzepatide pen is a sealed, pre-filled pen containing 40 mg of tirzepatide in solution, filled by the manufacturer, not by ALTA PEPTIDES. A pen arrives ready-made, where a tirzepatide vial is a dry powder that a laboratory reconstitutes itself. Our pen vs vial guide explains the trade-offs, which are the same for every peptide in this class. The certificate of analysis for the tirzepatide in each lot will be published on this page before the pen goes on sale.

UK status

Tirzepatide is the active ingredient in Mounjaro, a prescription-only medicine licensed in the UK for type 2 diabetes and weight management. This pen is not Mounjaro, is not made or endorsed by Eli Lilly, and is not a medicine. It is research-grade tirzepatide supplied for laboratory research only, not for human use. Anyone seeking treatment should speak to a doctor or a registered pharmacy. Our guide to UK peptide law explains the difference between licensed medicines and research compounds.

Availability

The tirzepatide 40 mg pen is arriving soon in UK stock. The price, release date and lot certificate will be posted here first. Register above to be told the day it is available.

Tirzepatide as a reference compound in incretin research

Tirzepatide has become the reference compound, or comparator, that newer incretin drugs are measured against. A phase 3 study registered on ClinicalTrials.gov (NCT06662383) compares retatrutide with tirzepatide in adults who have obesity. CagriSema, Novo Nordisk's amylin combination, was tested against tirzepatide in the REDEFINE 4 trial, which our amylin agonists explainer covers.

The UK prescribing information for Mounjaro sets out why the molecule matters to the study of metabolic regulation. It states that GIP and GLP-1 receptors are both expressed in the areas of the brain important to appetite regulation. It also reports an in-vitro finding: in cultured human adipocytes, tirzepatide acts on GIP receptors to regulate glucose uptake.

None of that research was done with the pen on this page. For UK researchers the position is unchanged. This UK research peptide listing is not held in ALTA PEPTIDES UK stock, it is not Mounjaro and it is not a licensed medicine. Its certificate of analysis will be published here before the pen goes on sale. It is listed for research purposes, strictly for laboratory research, and ALTA gives no guidance on human use.

For laboratory research use only. Not for human or veterinary use, not for diagnostic or therapeutic use, not a medicine or a supplement. Sold to researchers aged 18 and over. Nothing on this page is a recommendation for any use of this compound.
§ 03

Questions

When will the tirzepatide pen be available?
It is arriving soon in UK stock. The price, release date and the lot certificate will be posted on this page first. Register your email above to be told the day it is available.
How much will the tirzepatide 40 mg pen cost?
The price is not set yet. It will be published here before release, with the price per milligram so it can be compared with other pens and vials.
What is tirzepatide?
Tirzepatide is a 39-amino-acid synthetic peptide that activates both the GIP and GLP-1 receptors. It was developed by Eli Lilly and is the active ingredient in the licensed medicines Mounjaro and Zepbound.
Is this Mounjaro?
No. Mounjaro is Eli Lilly's licensed, prescription-only medicine. This is a research-grade tirzepatide pen from a third-party manufacturer, supplied for laboratory research only and not for human use.
Is tirzepatide a peptide?
Yes. Tirzepatide is a peptide of 39 amino acids, based on the GIP hormone sequence, with a C20 fatty diacid attached so that it lasts about five days in the blood.
Tirzepatide vs retatrutide: what is the difference?
Tirzepatide acts on two receptors, GIP and GLP-1. Retatrutide acts on three, adding glucagon. In separate trials tirzepatide produced 20.9% average weight loss at 72 weeks and retatrutide 28.3% at 80 weeks; a direct head-to-head trial is due to report later.
Tirzepatide vs semaglutide: which did better in trials?
In SURMOUNT-5, a direct 72-week comparison published in 2025, tirzepatide produced 20.2% average weight loss against 13.7% for semaglutide.
Can you buy tirzepatide in the UK?
As a medicine, tirzepatide (Mounjaro) is prescription-only and comes from a doctor or registered pharmacy. ALTA PEPTIDES will supply this pen as a research compound for laboratory use only, to researchers aged 18 and over.
What is a tirzepatide research pen?
A tirzepatide research pen is a sealed, pre-filled pen sold as a laboratory research compound rather than as a medicine. This tirzepatide peptide pen will hold 40 mg of tirzepatide in solution, filled by a third-party manufacturer, with a certificate of analysis published for each lot. It is not Mounjaro and it is not for human use.
Do tirzepatide peptides come as a pen or a vial?
Both formats exist. Tirzepatide peptides for laboratory research are supplied either as a sealed pre-filled pen, which holds the peptide in solution, or as a vial of dry powder that a laboratory reconstitutes itself. This listing is the 40 mg pen; as a tirzepatide research peptide it is for laboratory use only.
How does tirzepatide act on the GIP receptor and the GLP-1 receptor?
Tirzepatide is a dual agonist of two incretin receptors: the glucose-dependent insulinotropic polypeptide (GIP) receptor and the glucagon-like peptide-1 (GLP-1) receptor. The UK prescribing information for Mounjaro states that both receptors are present on the endocrine cells of the pancreas, that tirzepatide's activity on the GIP receptor is similar to the native hormone, and that it enhances insulin secretion in a glucose-dependent manner, delays gastric emptying and improves glycaemic control in patients with type 2 diabetes. That combined GLP-1 and GIP signal is why this dual incretin receptor agonist is studied in incretin research and in metabolic research more widely.
What did the SURPASS and SURMOUNT trials measure?
SURPASS and SURMOUNT are the phase 3 programmes behind the licensed medicine. The SURPASS trials studied type 2 diabetes, with glycaemic control as the primary objective. In SURPASS-2 (New England Journal of Medicine, 2021), 1,879 patients received once-weekly tirzepatide 5 mg, 10 mg or 15 mg or semaglutide 1 mg for 40 weeks, and glycated haemoglobin fell by 2.01 to 2.30 percentage points on tirzepatide against 1.86 on semaglutide. The SURMOUNT trials measured weight reduction in adults with obesity or overweight, and that trial data is set out above. The UK prescribing information also records acute pancreatitis in patients treated with tirzepatide.
Does the pen need reconstituting like tirzepatide vials?
No. The pen holds tirzepatide already in solution. The lyophilised format is the vial: tirzepatide vials hold a lyophilised powder that a laboratory reconstitutes with bacteriostatic water before use. ALTA lists the 40 mg pen only, with no tirzepatide vial. The licensed medicine is a liquid too: the UK prescribing information describes Mounjaro as a solution for injection in a pre-filled pen, stored in a refrigerator at 2 to 8 °C, in line with the storage shown in the specification above. Our pen vs vial guide compares the two formats.
Tirzepatide UK status: is the pen in stock, and is it a medicine?
No on both counts. This tirzepatide peptide UK listing is a research item that is not in stock. It is not Mounjaro and it is not a licensed medicine. It is a tirzepatide research peptide: a research compound for research use, not for human consumption or veterinary use. The COA for every batch will be published on this page before it goes on sale. Tirzepatide as a treatment is a prescription-only medicine, so treatment questions belong with a prescriber, and ALTA gives no medical advice. Our guide to UK peptide law covers the laws and regulations that separate licensed medicines from research compounds.
Is tirzepatide a GLP-1 receptor agonist peptide?
In part. Tirzepatide is a single peptide that activates two receptors, so it is a GIP receptor agonist as well. The UK prescribing information for Mounjaro calls it a long acting GIP and GLP-1 receptor agonist and states that its activity on the GLP-1 receptor is lower than that of the native GLP-1 hormone. Semaglutide acts on the GLP-1 receptor alone.
What laboratory work came before the tirzepatide trials?
The discovery paper describes it (Coskun and colleagues, Molecular Metabolism, 2018). The molecule, then coded LY3298176, was characterised with in-vitro signalling assays in cell lines expressing the incretin receptors, and then in mice, where the authors reported falls in body weight and food intake greater than with a GLP-1 receptor agonist. The same paper reports a phase 1 study in which 142 people received at least one dose of LY3298176, dulaglutide or placebo.
§ 04

In stock now

See all →
Retatrutide Pen pre-filled penNewNo. 014
Weight & MetabolicPen

Retatrutide Pen

Synedica pre-filled pen: 40 mg retatrutide, with needles

Size
40 mg pen
HPLC
99.752%
Lot
07022601
£139.99£3.50/mg